Application number | Title of the application | Filing Date | Status |
---|
Array
(
[id] => 16627522
[patent_doc_number] => 20210046175
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-18
[patent_title] => HIV VACCINES COMPRISING ONE OR MORE POPULATION EPISENSUS ANTIGENS
[patent_app_type] => utility
[patent_app_number] => 17/008335
[patent_app_country] => US
[patent_app_date] => 2020-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19961
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17008335
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/008335 | HIV vaccines comprising one or more population episensus antigens | Aug 30, 2020 | Issued |
Array
(
[id] => 16627521
[patent_doc_number] => 20210046174
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-18
[patent_title] => HIV VACCINES COMPRISING ONE OR MORE POPULATION EPISENSUS ANTIGENS
[patent_app_type] => utility
[patent_app_number] => 17/008289
[patent_app_country] => US
[patent_app_date] => 2020-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19967
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17008289
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/008289 | HIV vaccines comprising one or more population episensus antigens | Aug 30, 2020 | Issued |
Array
(
[id] => 16673457
[patent_doc_number] => 20210062220
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-04
[patent_title] => METHODS AND CONSTRUCTS FOR PRODUCTION OF LENTIVIRAL VECTOR
[patent_app_type] => utility
[patent_app_number] => 17/001114
[patent_app_country] => US
[patent_app_date] => 2020-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11114
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17001114
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/001114 | Methods and constructs for production of lentiviral vector | Aug 23, 2020 | Issued |
Array
(
[id] => 18341281
[patent_doc_number] => 11638750
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-02
[patent_title] => Methods for generating a Zikv immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 protein
[patent_app_type] => utility
[patent_app_number] => 17/000768
[patent_app_country] => US
[patent_app_date] => 2020-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 17515
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17000768
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/000768 | Methods for generating a Zikv immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 protein | Aug 23, 2020 | Issued |
Array
(
[id] => 16657418
[patent_doc_number] => 20210054054
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => ENGINEERING PH-DEPENDENT ANTIGEN BINDING ACTIVITY INTO ANTI-HIV ANTIBODIES WITH IMPROVED PHARMACOKINETICS
[patent_app_type] => utility
[patent_app_number] => 16/997547
[patent_app_country] => US
[patent_app_date] => 2020-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7142
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16997547
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/997547 | Engineering pH-dependent antigen binding activity into anti-HIV antibodies with improved pharmacokinetics | Aug 18, 2020 | Issued |
Array
(
[id] => 17443760
[patent_doc_number] => 20220064265
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => Episomal Expression of Potent Immunoglobulins Derived from Human Blood or Convalescent Plasma to Enable Short term Vaccination / Immunization to COVID, COVID-19 and Mutants and Other Pandemic and non-Pandemic Viruses designed from Rapid FDA approval.
[patent_app_type] => utility
[patent_app_number] => 16/995829
[patent_app_country] => US
[patent_app_date] => 2020-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17465
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 435
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16995829
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/995829 | Episomal Expression of Potent Immunoglobulins Derived from Human Blood or Convalescent Plasma to Enable Short term Vaccination / Immunization to COVID, COVID-19 and Mutants and Other Pandemic and non-Pandemic Viruses designed from Rapid FDA approval. | Aug 17, 2020 | Pending |
Array
(
[id] => 17076020
[patent_doc_number] => 11112412
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-09-07
[patent_title] => SARS-CoV-2 surrogate virus neutralization assay test kit
[patent_app_type] => utility
[patent_app_number] => 16/939405
[patent_app_country] => US
[patent_app_date] => 2020-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 30
[patent_no_of_words] => 20380
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16939405
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/939405 | SARS-CoV-2 surrogate virus neutralization assay test kit | Jul 26, 2020 | Issued |
Array
(
[id] => 16452618
[patent_doc_number] => 20200362044
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-19
[patent_title] => Methods of Treating Cytokine Storm Infections, Including COVID-19, By Inhibiting CCR5/CCL5 (RANTES) Interaction, and Compositions for Practicing the Same
[patent_app_type] => utility
[patent_app_number] => 16/932636
[patent_app_country] => US
[patent_app_date] => 2020-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11037
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16932636
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/932636 | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions | Jul 16, 2020 | Issued |
Array
(
[id] => 16391049
[patent_doc_number] => 20200331990
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-22
[patent_title] => MOBILIZING HIV-INFECTED CELLS FROM LYMPHATIC RESERVOIRS
[patent_app_type] => utility
[patent_app_number] => 16/921682
[patent_app_country] => US
[patent_app_date] => 2020-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8082
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16921682
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/921682 | MOBILIZING HIV-INFECTED CELLS FROM LYMPHATIC RESERVOIRS | Jul 5, 2020 | Abandoned |
Array
(
[id] => 16359416
[patent_doc_number] => 20200316167
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-08
[patent_title] => Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
[patent_app_type] => utility
[patent_app_number] => 16/912199
[patent_app_country] => US
[patent_app_date] => 2020-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16536
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16912199
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/912199 | Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4 | Jun 24, 2020 | Abandoned |
Array
(
[id] => 16466806
[patent_doc_number] => 20200368343
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => ZIKA VIRUS MRNA VACCINES
[patent_app_type] => utility
[patent_app_number] => 16/897859
[patent_app_country] => US
[patent_app_date] => 2020-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16897859
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/897859 | ZIKA VIRUS MRNA VACCINES | Jun 9, 2020 | Pending |
Array
(
[id] => 16329890
[patent_doc_number] => 20200300856
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-24
[patent_title] => RECOMBINANT BACULOVIRUSES AND THEIR USES IN DETECTING ARTHROPOD-BORNE VIRUS
[patent_app_type] => utility
[patent_app_number] => 16/892289
[patent_app_country] => US
[patent_app_date] => 2020-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5527
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16892289
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/892289 | RECOMBINANT BACULOVIRUSES AND THEIR USES IN DETECTING ARTHROPOD-BORNE VIRUS | Jun 3, 2020 | Abandoned |
Array
(
[id] => 16483975
[patent_doc_number] => 20200377576
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-03
[patent_title] => HIV-1 SPECIFIC IMMUNOGEN COMPOSITIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/887710
[patent_app_country] => US
[patent_app_date] => 2020-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17749
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16887710
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/887710 | HIV-1 SPECIFIC IMMUNOGEN COMPOSITIONS AND METHODS OF USE | May 28, 2020 | Abandoned |
Array
(
[id] => 16483975
[patent_doc_number] => 20200377576
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-03
[patent_title] => HIV-1 SPECIFIC IMMUNOGEN COMPOSITIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/887710
[patent_app_country] => US
[patent_app_date] => 2020-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17749
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16887710
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/887710 | HIV-1 SPECIFIC IMMUNOGEN COMPOSITIONS AND METHODS OF USE | May 28, 2020 | Abandoned |
Array
(
[id] => 17095454
[patent_doc_number] => 20210283245
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-16
[patent_title] => Anti COVID-19 Therapies targeting nucleocapsid and spike proteins
[patent_app_type] => utility
[patent_app_number] => 16/883263
[patent_app_country] => US
[patent_app_date] => 2020-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8883
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16883263
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/883263 | Replication-defective adenoviruses comprising nucleic acids encoding SARS-CoV-2 s glycoprotein and modified N protein comprising an endosomal targeting sequence | May 25, 2020 | Issued |
Array
(
[id] => 18574307
[patent_doc_number] => 11730813
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-22
[patent_title] => Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/882354
[patent_app_country] => US
[patent_app_date] => 2020-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 34
[patent_figures_cnt] => 33
[patent_no_of_words] => 46671
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16882354
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/882354 | Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof | May 21, 2020 | Issued |
Array
(
[id] => 18558752
[patent_doc_number] => 11723977
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-15
[patent_title] => Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/882359
[patent_app_country] => US
[patent_app_date] => 2020-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 34
[patent_figures_cnt] => 33
[patent_no_of_words] => 46699
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16882359
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/882359 | Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof | May 21, 2020 | Issued |
Array
(
[id] => 17118780
[patent_doc_number] => 11129890
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-09-28
[patent_title] => Non-integrating
[patent_app_type] => utility
[patent_app_number] => 16/877839
[patent_app_country] => US
[patent_app_date] => 2020-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 15
[patent_no_of_words] => 26012
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16877839
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/877839 | Non-integrating | May 18, 2020 | Issued |
Array
(
[id] => 16466810
[patent_doc_number] => 20200368347
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH GP120 V3 GLYCAN-DIRECTED ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/877292
[patent_app_country] => US
[patent_app_date] => 2020-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33442
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -47
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16877292
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/877292 | Methods of identifying HIV patients sensitive to therapy with GP120 V3 glycan-directed antibodies | May 17, 2020 | Issued |
Array
(
[id] => 18233210
[patent_doc_number] => 11597759
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-03-07
[patent_title] => Multispecific antibodies that target HIV GP120 and CD3
[patent_app_type] => utility
[patent_app_number] => 16/867924
[patent_app_country] => US
[patent_app_date] => 2020-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56224
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 183
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867924
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/867924 | Multispecific antibodies that target HIV GP120 and CD3 | May 5, 2020 | Issued |